---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-004158"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:26:22.106989+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incannex reports >$70M cash, two positive Phase 2 readouts, FDA Fast Track; outlines 2026 outlook

## Summary
- Cash and cash equivalents >$70M, providing operating runway into 2027.
- IHL-42X (OSA) Phase 2 RePOSA: up to 83% AHI reduction; FDA Fast Track designation.
- PSX-001 (GAD) Phase 2: statistically significant improvement on HAM-A vs placebo.
- Completed $12.5M private placement; eliminated all Series A warrants.
- Authorized $20M share repurchase program.

## SEC filing metadata
- accession: 0001213900-26-004158
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026004158/0001213900-26-004158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026004158/ea0272883-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-004158
- JSON: https://secwatch.observer/filing/0001213900-26-004158.json
- Plain text: https://secwatch.observer/filing/0001213900-26-004158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.